Zimbuck – Your Market. Your Community.
BREAKING: Senseonics surges 18% in premarket as Q3 revenue jumps 140%.

Senseonics Holdings (NASDAQ: SENS), the maker of the Eversense 365 long-term implantable glucose monitor, reported third-quarter revenue of $19.6 million — up about 140% year over year from $8.1 million and well above the $16.2 million consensus. GAAP EPS of -$0.50 beat the -$0.52 estimate, and gross margin reached about 62%.

The company raised full-year 2026 revenue guidance to $68 million–$70 million from $62 million–$66 million (93%–98% growth) and lifted its gross-margin outlook to more than 60%. Shares jumped 18% in Tuesday premarket trading after a 14% gain on Monday.

Sources: Senseonics Q3 2026 company release (GlobeNewswire), Seeking Alpha.

#Senseonics #SENS #Earnings #Stocks #Investing #MedTech #CGM
Like
Love
6
101 Views